CDK1 and Miyoshi myopathy: To assess whether the CDC25C inhibitor NSC95397 could reverse KIF22-mediated regulation of proliferation and cell cycle transition by inhibiting the CDC25C/CDk1/cyclinB1 pathway, we treated KIF22-overexpressed MM cells with NCS95397.